Ix Biopharma Sustainability Profile
Ix Biopharma Ltd, headquartered in Singapore (SG), is a pioneering biopharmaceutical company specialising in the development of innovative drug delivery systems. Founded in 2008, Ix Biopharma has made significant strides in the industry, particularly with its proprietary WaferiX™ technology, which enhances the delivery of therapeutics through sublingual administration. The company focuses on pain management and other therapeutic areas, offering unique products that provide rapid onset and improved bioavailability. With a strong commitment to research and development, Ix Biopharma has positioned itself as a leader in the biopharmaceutical sector, achieving notable milestones in product development and regulatory approvals. Its dedication to advancing patient care through innovative solutions underscores its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 20 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ix Biopharma's reported carbon emissions
In 2025, Ix Biopharma reported Scope 2 emissions of approximately 1,026,000 kg CO2e in Australia. This marks an increase from 2024, where global Scope 2 emissions were about 949,000 kg CO2e, and Australian emissions for the same year were also around 949,000 kg CO2e. The company’s emissions in 2023 were approximately 937,000 kg CO2e globally, and in 2022, they reported about 714,000 kg CO2e globally. The highest recorded emissions were in 2021, with approximately 997,000 kg CO2e globally. Despite these figures, Ix Biopharma has not set specific reduction targets or initiatives, nor do they have any climate pledges or commitments documented. The emissions data is not cascaded from any parent organization, indicating that the figures are independently reported by Ix Biopharma. The company continues to focus on its sustainability reporting, but further details on specific climate commitments or reduction strategies are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Ix Biopharma's Industry?
How Carbon Intensive is Ix Biopharma's Location?
Ix Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ix Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
